Bicycle Therapeutics (BCYC) Assets (2018 - 2026)
Bicycle Therapeutics' (BCYC) quarterly Assets came in at $606.6 million in Q2 2026, down 27.11% YoY from $832.2 million in Q2 2025, and down 7.02% on a QoQ basis from $652.4 million in Q1 2026.
Bicycle Therapeutics (BCYC) Assets (2018 - 2026) Analysis & Trends
Bicycle Therapeutics (BCYC) has 9 years of Assets data on file, last reported at $606.6 million in Q2 2026.
- Quarterly Assets fell 27.11% year-over-year to $606.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $606.6 million (down 27.11% YoY) and the FY2025 annual result came in at $717.6 million, down 25.01% from the prior year.
- Assets eased to $606.6 million in Q2 2026, from $652.4 million in the prior quarter.
- In the past five years, Assets ranged from a high of $1.1 billion in Q2 2024 to a low of $410.6 million in Q4 2022.
- A 5-year average of $659.1 million and a median of $622.6 million in 2023 frame the typical range for Assets.
- Annual changes were most pronounced in 2024 — Assets surged 132.81% — and 2026, when it decreased 27.11%.
- Tracing BCYC's Assets over 5 years: stood at $410.6 million in 2022, then soared by 44.99% to $595.3 million in 2023, then jumped by 60.73% to $956.9 million in 2024, then declined by 25.01% to $717.6 million in 2025, then declined by 15.47% to $606.6 million in 2026.
- The last three Assets figures came in at $606.6 million (Q2 2026), $652.4 million (Q1 2026), and $717.6 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Bicycle Therapeutics | 272.28 Mn | 272.28 Mn | - | 606.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 606.58 Mn |
| Mar 31, 2026 | 652.40 Mn |
| Dec 31, 2025 | 717.60 Mn |
| Sep 30, 2025 | 763.95 Mn |
| Jun 30, 2025 | 832.18 Mn |
| Mar 31, 2025 | 883.89 Mn |
| Dec 31, 2024 | 956.87 Mn |
| Sep 30, 2024 | 996.75 Mn |
| Jun 30, 2024 | 1.06 Bn |
| Mar 31, 2024 | 547.14 Mn |
| Dec 31, 2023 | 595.34 Mn |
| Sep 30, 2023 | 638.68 Mn |
| Jun 30, 2023 | 454.17 Mn |
| Mar 31, 2023 | 428.80 Mn |
| Dec 31, 2022 | 410.61 Mn |
| Sep 30, 2022 | 417.15 Mn |
| Jun 30, 2022 | 445.48 Mn |
| Mar 31, 2022 | 459.56 Mn |
| Dec 31, 2021 | 479.79 Mn |
| Sep 30, 2021 | 281.33 Mn |